Quick Answer
IO Biotech, Inc. reported Diluted EPS of $1.45 per share (loss) for fiscal year 2024.
IO Biotech, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$1.45 | +26.8% |
| 2023 | -$1.98 | +20.2% |
| 2022 | -$2.48 | +85.7% |
| 2021 | -$17.30 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.13 | +63.9% | +67.5% |
| June 30, 2025 | -$0.40 | -29.0% | -17.6% |
| March 31, 2025 | -$0.34 | -13.3% | +5.6% |
| September 30, 2024 | -$0.36 | +16.3% | -16.1% |
| June 30, 2024 | -$0.31 | +58.1% | -3.3% |
| March 31, 2024 | -$0.30 | +49.2% | +30.2% |
| September 30, 2023 | -$0.43 | +20.4% | +41.9% |
| June 30, 2023 | -$0.74 | -15.6% | -25.4% |
- IO Biotech, Inc. showed an increase of +26.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2024 period, IO Biotech, Inc.’s diluted eps has grown by 91.6% (from $17.30 per share (loss) to $1.45 per share (loss)).
- The most recent figure is from IO Biotech, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: